An established inhibitor of dynamin-related protein 1 (Drp1), 3-(2,4-dichloro-5-methoxyphenyl)-2-thioxoquinazoline-4-one (mdivi-1), was recently reported also to show potent puromycin-sensitive aminopeptidase (PSA)-inhibitory activity. Herein, we report structural development of mdivi-1 derivatives and structure–activity relationship (SAR) analysis of the synthesized compounds, as well as the structurally related PSA-specific inhibitor 3-(2,6-diethylphenyl)quinazoline-2,4-dione (PAQ-22), with the aim of identifying key structural features for inhibitory activity in order to develop selective inhibitors of Drp1, which is a potential target for treatment of Huntington’s disease. Among the synthesized compounds, 3-(4-chloro-3-methoxyphenyl)-2-thioxoquinazoline-4-one (10g) exhibited more potent Drp1-inhibitory activity than mdivi-1 with high selectivity for Drp1 over PSA.
已知的dynamin相关蛋白1(Drp1)
抑制剂——3-(2,4-二
氯-5-甲氧苯基)-2-
噻唑啉酮(mdivi-1),近期还被报道显示出强大的
嘌呤霉素敏感性
氨基肽酶(P
SA)抑制活性。在此,我们报道了mdivi-1衍
生物的结构开发、合成化合物的构效关系(
SAR)分析,以及结构相关的P
SA特异性
抑制剂3-(2,6-二
乙基苯基)
喹唑啉-2,4-二酮(PAQ-22),旨在识别抑制活性的关键结构特征,从而开发针对Drp1的选择性
抑制剂,Drp1是治疗亨廷顿病的潜在靶点。在合成化合物中,3-(4-
氯-3-甲氧苯基)-2-
噻唑啉酮(10g)表现出比mdivi-1更强大的Drp1抑制活性,并对Drp1显示出高度选择性优于P
SA。